Oncology Biomarkers: Discovery, Validation, and Clinical Use

Seminars in Oncology Nursing

Volumn 28, Issue 2, 2012, Pages 93-98

  Heckman Stoddard, Brandy M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; OncotypeDX; Sensitivity; Specificity; Validation

Indexed keywords

TUMOR MARKER;

ARTICLE; BIOASSAY; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; NEOPLASM; PATHOLOGY; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL ASSAY; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860234637     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2012.03.003     Document Type: Article

References (33)

1. Hulka B. Overview of biological markers. Biological markers in epidemiology 1990, 3-15. Oxford University Press, New York. B. Hulka, J. Griffith, T.C. Wilcosky (Eds.).
2. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. National Institutes of Health Director's Initiative on Biomarkers and Surrogate Endpoints Working Group.
3. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
4. Wade A. Derivation versus validation. Arch Dis Child 2000, 83:459-460.
5. Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 2003, 3:525-529.
6. Prorok P.C., Andriole G.L., Bresalier R.S., et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000, 21:273S-309S.
7. Oken M.M., Hocking W.G., Kvale P.A., et al. Screening by chest radiograph and lung cancer mortality. JAMA 2011, 306:1865-1873.
8. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
9. O'Rourke M.E. The prostate-specific antigen screening conundrum: examining the evidence. Semin Oncol Nurs 2011, 27:251-259.
10. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744.
11. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
12. Press M.F., Sauter G., Bernstein L., et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11:6598-6607.
13. Puntmann V.O. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad Med J 2009, 85:538-545.
14. Carlson R.W., Allred D.C., Anderson B.O., et al. Invasive breast cancer. J Natl Compr Canc Netw 2011, 9:136-222.
15. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
16. Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
17. Gruvberger S., Ringner M., Chen Y., et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61:5979-5984.
18. Ramaswamy S., Ross K.N., Lander E.S., et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
19. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
20. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
21. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
22. Cobleigh M.A., Tabesh B., Bitterman P., et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005, 11:8623-8631.
23. Esteban J, Baker J, Cronin M, et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue [Abstract]. ASCO Annual Meeting; Chicago, IL, 2003.
24. Cronin M., Sangli C., Liu M.-L., et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007, 53:1084-1091.
25. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?. Genet Med 2009, 11:66-73.
26. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
27. Chien R., Hornberger J. PCN158 treatment decision change with 21-gene recurrence score in patients with early stage breast cancer (ESBC): a meta-analysis. Value Health 2010, 13:A281. [abstract].
28. Goldstein L.J., Gray R., Badve S., et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008, 26:4063-4071.
29. Dowsett M., Cuzick J., Wale C., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28:1829-1834.
30. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65.
31. Southwest Oncology Group. Tamoxifen citrate, letrozole, anastrozole, or exemestane with or without chemotherapy in treating patients with invasive RxPONDER breast cancer. Available at: (accessed January 5, 2012). http://www.clinicaltrials.gov/ct2/show/NCT01272037?term=RxPONDER&rank=1.
32. Eastern Cooperative Oncology Group. Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial). Available at: (accessed January 5, 2012). http://www.clinicaltrials.gov/ct2/show/study/NCT00310180?term=TAILORx&rank=1&show_desc=Y#desc.
33. Solin L, Gray R, Baehner F, et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194 (Abstract S4-06). 2011 San Antonio Breast Cancer Symposium; San Antonio, TX; 2011.